Cerevel Stock Analysis

CERE
 Stock
  

USD 33.47  3.32  9.02%   

The latest price surge of Cerevel Therapeutics Hldg could raise concerns from shareholders as the firm is trading at a share price of 33.47 on 957,794 in volume. The company management teams may have good odds in positioning the firm resources to exploit market volatility in September. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.24. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Cerevel Therapeutics partners.
Continue to Trending Equities.
  
The Cerevel Therapeutics stock analysis report makes it easy to digest most publicly released information about Cerevel Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Cerevel Stock analysis module also helps to analyze the Cerevel Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Cerevel Stock Analysis Notes

About 19.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.54. Cerevel Therapeutics Hldg had not issued any dividends in recent years. The entity had 1:8 split on the April 9, 2015. Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts. Cerevel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 228 people. For more info on Cerevel Therapeutics Hldg please contact Richard Hamilton at 844 304 2048 or go to https://www.cerevel.com.

Cerevel Therapeutics Hldg Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Cerevel Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Cerevel Therapeutics Hldg or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Cerevel Therapeutics is way too risky over 90 days horizon
Cerevel Therapeutics appears to be risky and price may revert if volatility continues
Cerevel Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 2.72 M. Net Loss for the year was (242.65 M) with loss before overhead, payroll, taxes, and interest of (2.55 M).
Cerevel Therapeutics Hldg currently holds about 542.94 M in cash with (209.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.66.
Cerevel Therapeutics has a frail financial position based on the latest SEC disclosures
Over 84.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.nasdaq.com: Stem, Inc. Q2 Loss Drops - Nasdaq

Cerevel Therapeutics Hldg Upcoming and Recent Events

Earnings reports are used by Cerevel Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Cerevel Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report10th of November 2021
Next Fiscal Quarter End30th of September 2021
Last Quarter Report30th of June 2021
Last Financial Announcement30th of September 2020

Cerevel Largest EPS Surprises

Earnings surprises can significantly impact Cerevel Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-08-01
2022-06-30-0.48-0.62-0.1429 
2021-03-24
2020-12-31-0.45-0.270.1840 
View All Earnings Estimates

Cerevel Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Cerevel Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Cerevel Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Cerevel Therapeutics Hldg specific information freely available to individual and institutional investors to make a timely investment decision.
1st of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
15th of June 2022
Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Unclassified Corporate Event. Completion of Acquisition or Disposition of Assets
View
10th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
7th of April 2022
Unclassified Corporate Event
View
3rd of March 2022
Unclassified Corporate Event
View
1st of March 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
9th of February 2022
Unclassified Corporate Event
View
10th of November 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View

Cerevel Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 4.22 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cerevel Therapeutics's market, we take the total number of its shares issued and multiply it by Cerevel Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Cerevel Profitablity

Cerevel Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Cerevel Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Cerevel Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Cerevel Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Cerevel Therapeutics' profitability requires more research than a typical breakdown of Cerevel Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Average Assets(0.41) (0.44) 
Return on Average Equity(0.49) (0.53) 
Return on Invested Capital(1.15) (1.24) 
Return on Sales(11.89) (12.83) 

Management Efficiency

The entity has return on total asset (ROA) of (29.43) % which means that it has lost $29.43 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (56.33) %, meaning that it created substantial loss on money invested by shareholders. Cerevel Therapeutics management efficiency ratios could be used to measure how well cerevel therapeutics hldg manages its routine affairs as well as how well it operates its assets and liabilities. As of August 9, 2022, Return on Average Assets is expected to decline to -0.44. In addition to that, Return on Average Equity is expected to decline to -0.53. The current year Tangible Assets Book Value per Share is expected to grow to 5.32, whereas Total Assets are forecasted to decline to about 604.8 M.
Last ReportedProjected for 2022
Book Value per Share 4.24  4.39 
Enterprise Value over EBIT(19.00) (20.50) 
Enterprise Value over EBITDA(18.76) (20.23) 
Price to Book Value 8.25  8.31 
Tangible Assets Book Value per Share 5.04  5.32 
Enterprise Value4.2 BB
Tangible Asset Value688.9 M604.8 M

Technical Drivers

As of the 9th of August, Cerevel Therapeutics shows the Risk Adjusted Performance of 0.093, mean deviation of 4.45, and Downside Deviation of 5.8. Cerevel Therapeutics Hldg technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Cerevel Therapeutics Hldg, which can be compared to its rivals. Please confirm Cerevel Therapeutics Hldg treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Cerevel Therapeutics Hldg is priced correctly, providing market reflects its regular price of 33.47 per share. Given that Cerevel Therapeutics has jensen alpha of 0.4883, we suggest you to validate Cerevel Therapeutics Hldg's prevailing market performance to make sure the company can sustain itself at a future point.

Cerevel Therapeutics Hldg Price Movement Analysis

The output start index for this execution was thirty-two with a total number of output elements of twenty-nine. The MESA Adaptive Moving Average indicator adapts to Cerevel Therapeutics Hldg price movement based on the rate change of phase as measured by the Hilbert Transform Discriminator.
.

Cerevel Therapeutics Hldg Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cerevel Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cerevel Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cerevel Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Renger John over two weeks ago via Macroaxis 
Exercise or conversion by Renger John of 25000 shares of Cerevel Therapeutics subject to Rule 16b-3
Renger John over a month ago via Macroaxis 
Exercise or conversion by Renger John of 1105 shares of Cerevel Therapeutics subject to Rule 16b-3
Sulzberger Gabrielle over a month ago via Macroaxis 
Exercise or conversion by Sulzberger Gabrielle of 14270 shares of Cerevel Therapeutics subject to Rule 16b-3
Koppel Adam over a month ago via Macroaxis 
Acquisition by Koppel Adam of 23459 shares of Cerevel Therapeutics subject to Rule 16b-3
Bodenrader Mark over two months ago via Macroaxis 
Acquisition by Bodenrader Mark of 18932 shares of Cerevel Therapeutics subject to Rule 16b-3
Renger John over three months ago via Macroaxis 
Exercise or conversion by Renger John of 45000 shares of Cerevel Therapeutics subject to Rule 16b-3
Pf Equity Holdings 1 Bv over three months ago via Macroaxis 
Acquisition or disposition of Cerevel Therapeutics securities by Pf Equity Holdings 1 Bv
Renger John over three months ago via Macroaxis 
Exercise or conversion by Renger John of 10000 shares of Cerevel Therapeutics subject to Rule 16b-3
Renger John over three months ago via Macroaxis 
Exercise or conversion by Renger John of 20000 shares of Cerevel Therapeutics subject to Rule 16b-3
Renger John over three months ago via Macroaxis 
Exercise or conversion by Renger John of 30000 shares of Cerevel Therapeutics subject to Rule 16b-3
Renger John over three months ago via Macroaxis 
Exercise or conversion by Renger John of 25000 shares of Cerevel Therapeutics subject to Rule 16b-3
Tregoning Kathleen over three months ago via Macroaxis 
Acquisition by Tregoning Kathleen of 63321 shares of Cerevel Therapeutics subject to Rule 16b-3

Cerevel Therapeutics Technical and Predictive Indicators

Cerevel Therapeutics Forecast Models

Cerevel Therapeutics time-series forecasting models is one of many Cerevel Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cerevel Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Cerevel Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cerevel Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cerevel shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Cerevel Therapeutics. By using and applying Cerevel Stock analysis, traders can create a robust methodology for identifying Cerevel entry and exit points for their positions.
Last ReportedProjected for 2022
EBITDA Margin(11.61) (12.53) 
Gross Margin(1.08) (1.11) 
Profit Margin(11.90) (12.84) 
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts. Cerevel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 228 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Cerevel Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Content Syndication Now

   

Content Syndication

Quickly integrate customizable finance content to your own investment portal
All  Next Launch Module
Continue to Trending Equities. Note that the Cerevel Therapeutics Hldg information on this page should be used as a complementary analysis to other Cerevel Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Complementary Tools for Cerevel Stock analysis

When running Cerevel Therapeutics Hldg price analysis, check to measure Cerevel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cerevel Therapeutics is operating at the current time. Most of Cerevel Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cerevel Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cerevel Therapeutics' price. Additionally, you may evaluate how the addition of Cerevel Therapeutics to your portfolios can decrease your overall portfolio volatility.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Is Cerevel Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cerevel Therapeutics. If investors know Cerevel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cerevel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
B
Return On Assets
-0.36
Return On Equity
-0.75
The market value of Cerevel Therapeutics Hldg is measured differently than its book value, which is the value of Cerevel that is recorded on the company's balance sheet. Investors also form their own opinion of Cerevel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cerevel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cerevel Therapeutics' market value can be influenced by many factors that don't directly affect Cerevel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cerevel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cerevel Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cerevel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.